IP Library Granted Patent US 8,986,933
Granted Patent B2
US 8,986,933 · App. 12/315,758 · Granted Mar 24, 2015

Selective detection of human rhinovirus

Inventors: Xiaoyan Lu (Atlanta, GA); Dean Erdman (Decatur, GA)
Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control
C12Q1/701
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,986,933
App. No.
12/315,758
Granted
Mar 24, 2015
Kind
B2
Abstract

A process for detecting human rhinovirus nucleic acid in a biological sample, includes producing an amplification product by amplifying an human bocavirus nucleotide sequence using a forward primer of SEQ ID NO: 1, and a reverse primer of SEQ ID NO: 2, and measuring said amplification product to detect human rhinovirus in said biological sample. Also provided are reagents and methods for detecting and distinguishing human rhinovirus from other viruses. A kit is provided for detecting and quantifying human rhinovirus in a biological sample.

Claims (15)

1. A process of detecting human rhinovirus in a biological sample comprising: producing an amplification product by amplifying a human rhinovirus nucleotide sequence using a forward primer homologous to a region within 356-563 of human rhinovirus, and a reverse primer homologous to a region within 356-563 of human rhinovirus, under conditions suitable for a polymerase chain reaction; and measuring said amplification product to detect human rhinovirus in said biological sample, wherein said forward primer is the isolated nucleotide having the sequence 5′-CPXGCCZGCGTGGY (SEQ ID NO: 1), wherein P is a pyrimidine derivative mimicking a C/T mix, X is LNA-dA, and Z is LNA-dT.

2. The process of claim 1 wherein said reverse primer is the sequence of SEQ ID NO: 2.

3. The process of claim 1 wherein said measuring comprises hybridizing a probe of SEQ ID NO: 3 to said amplification product.

4. The process of claim 3 wherein hybridizing said probe is under conditions suitable for a polymerase chain reaction; and further

detecting a first detection signal from said probe hybridized to said amplification product.

5. The process of claim 1 wherein said detecting diagnoses human rhinovirus infection.

6. The process of claim 1 further comprising comparing said first detection signal to a second detection signal, wherein said second detection signal results from detection of a second amplification product produced from a sequence of a virus selected from the group comprising human enterovirus, polio virus, respiratory syncytial virus, human metapneumovirus, human parainfluenza viruses 1-4, adenovirus, coronaviruses 229E and OC43, influenza viruses A and B, and human bocavirus, and the hybridization of a probe complementary to a sequence from one or more viruses of said group.

7. The process of claim 1 further comprising comparing said first detection signal to a second detection signal, wherein said second detection signal results from detection of a second amplification product produced from a sequence of human rhinovirus using a forward primer homologous to a region within 356-563 of human rhinovirus, and a reverse primer homologous to a region within 356-563 of human rhinovirus, and the hybridization of a probe complementary to a sequence from human rhinovirus.

8. The process of claim 7 wherein said second detection signal is generated in parallel with said first detection signal.

9. The process of claim 7 , wherein said second amplification product is generated by PCR amplification of a HRV target sequence.

10. The process of claim 1 wherein said detecting is by real-time RT-PCR.

11. A kit for detecting human rhinovirus infection comprising: a first forward primer with sequence that is the isolated nucleotide sequence 5′-CPXGCCZGCGTGGY (SEQ ID NO: 1), wherein P is a pyrimidine derivative, X is LNA-dA, and Z is LNA-dT, and a first reverse primer with SEQ ID NO: 2; and

a probe.

12. The kit of claim 11 wherein said probe has the sequence SEQ ID NO: 3.

13. An isolated oligonucleotide of sequence comprising 5′-CPXGCCZGCGTGGY (SEQ ID NO: 1), wherein P is a pyrimidine derivative-mimicking a C/T mix, X is LNA-dA, and Z is LNA-dT.

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY NAME PREVIOUSLY RECORDED ON REEL 022202 FRAME 0978. ASSIGNOR(S) HEREBY CONFIRMS THE CORRECTION OF ASSIGNEE TITLE.. Recorded May 7, 2009
From: LU, XIAOYAN; ERDMAN, DEAN D.
To: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION
Reel/Frame 022651/0901 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2009
From: LU, XIAOYAN; ERDMAN, DEAN D.
To: CDC/THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION
Reel/Frame 022202/0978 →
Continuity (1)
Related Publication 20100143881A1 · Jun 10, 2010